VVM
Versant Venture Management Portfolio holdings
AUM
$82.1M
This Quarter Return
-2.06%
1 Year Return
-26.22%
3 Year Return
+73.87%
5 Year Return
-1.11%
10 Year Return
+1,578.11%
AUM
$302M
AUM Growth
+$302M
(-41%)
Cap. Flow
-$215M
Cap. Flow
% of AUM
-71.1%
Top 10 Holdings %
Top 10 Hldgs %
99.8%
Holding
11
New
–
Increased
–
Reduced
4
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
CRISPR Therapeutics
CRSP
|
$169M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$22.8M |
| 3 |
Aligos Therapeutics
ALGS
|
$19.8M |
| 4 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$2.55M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CRISPR Therapeutics
CRSP
$4.71B
| $82.3M | 27.28% | 508,558 -1,046,402 | -67% | -$169M |
|
2
Passage Bio
PASG
$22.7M
| $65.7M | 21.76% | 4,959,769 | – | – |
|
|
3
Aligos Therapeutics
ALGS
$73.3M
| $47.3M | 15.67% | 2,320,381 -971,958 | -30% | -$19.8M |
|
|
GRTS
4
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $40.6M | 13.46% | 4,450,638 | – | – |
|
5
Adverum Biotechnologies
ADVM
$64.6M
| $17.7M | 5.88% | 5,068,233 | – | – |
|
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $15.5M | 5.13% | 820,720 -1,209,896 | -60% | -$22.8M |
|
7
Akero Therapeutics
AKRO
$3.74B
| $15.3M | 5.08% | 617,727 | – | – |
|
|
FLXN
8
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $8.23M | 2.73% | 1,000,000 -310,169 | -24% | -$2.55M |
|
9
Aprea Therapeutics
APRE
$9.09M
| $6.15M | 2.04% | 1,259,662 | – | – |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $2.37M | 0.79% | 543,753 | – | – |
|
|
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
| $591K | 0.2% | 101,855 | – | – |
|